Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799825 · ClinicalTrials.gov registry record · Phase 3
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 346
- Enrollment target
NCT00799825 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 346 participants.
The verdict
NCT00799825, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 346 participants
- Enrollment target
Study Summary
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
Interventions
- BIOLOGICAL GSK Biological's HPV vaccine GSK580299 (Cervarix™)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2009-01-01 |
| Est. Completion | 2012-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799825
The ClinicalTrials.gov registry entry for NCT00799825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK Biological's HPV vaccine GSK580299 (Cervarix™) is the first listed.
NCT00799825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799825 about?
NCT00799825 is a clinical study titled "Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US". This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
What is the current status of trial NCT00799825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 346 participants. The study started on 2009-01-01. Estimated completion is 2012-08-02.
What interventions are being tested in trial NCT00799825?
The interventions under investigation include: GSK Biological's HPV vaccine GSK580299 (Cervarix™) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00799825?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.